People: Amedisys Inc (AMED.OQ)

AMED.OQ on NASDAQ Stock Exchange Global Select Market

12 Aug 2020
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kemmerly, David 

Mr. David L. Kemmerly serves as Chief Legal and Government Affairs Officer of the Company. He previously served as General Counsel from October 2015 to March 2020 and Senior Vice President, Government Affairs from March 2015 to March 2020. He previously served as Interim General Counsel from March 30, 2015 to October 30, 2015. Mr. Kemmerly has over 27 years of experience in governmental affairs, with more than 19 years specializing in health care law and public policy. From September 2013 to March 2015, he served as Special Counsel at Adams and Reese LLP, a multidisciplinary law firm where he represented diverse health care interests before the state legislature and state agencies. Prior to Adams and Reese, Mr. Kemmerly served as Director of State Public Affairs of Humana, Inc. for six years where he was responsible for legislative and regulatory affairs and outcomes in all 50 states. In this role, he developed and led implementation of successful state legislative and regulatory strategies that helped protect the business interests of one of the nation’s largest health insurers with over 13 million medical enrollees. Mr. Kemmerly has extensive experience in state and national government relations, including serving as Associate Director of the Department of Government Affairs for the Louisiana State Medical Society where he lobbied state legislators, state regulatory agencies, and the U.S. Congress on issues impacting physicians and the practice of medicine. He also served as an attorney for the Louisiana State Senate, a political consultant for DLK Consulting Group, and on the staffs of a Governor and Member of Congress. Mr. Kemmerly is a member of the Board of the Amedisys Foundation (since March 2016).

Basic Compensation

Total Annual Compensation, USD 400,000
Restricted Stock Award, USD 841,468
Long-Term Incentive Plans, USD --
All Other, USD 620,692
Fiscal Year Total, USD 1,862,160

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 28,125 2,471,780.00
Name Fiscal Year Total

Paul Kusserow


Scott Ginn


Christopher Gerard


Sharon Brunecz


Michael North


Denise Bohnert

As Of  31 Dec 2019